Intellia Therapeutics, Inc.
Close on Oct 19, 2026
- Market cap
- $1.55B
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 5, 2026, after market close (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 6, 2026 | Before market open | $7.70M | – | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 11, 2026 | Before market open | $15.00M | $-0.81 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Feb 26, 2026 | Before market open | $23.00M | $-0.83 | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 6, 2025 | After market close | $13.80M | $-0.92 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 7, 2025 | Before market open | $14.20M | $-0.98 | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 8, 2025 | Before market open | $16.60M | – | – |
| Q4 FY2024 Ended Dec 31, 2024 | Feb 27, 2025 | Before market open | $12.90M | $-1.27 | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 7, 2024 | Before market open | $9.10M | $-1.34 | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 8, 2024 | Before market open | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 9, 2024 | Before market open | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Feb 22, 2024 | Before market open | – | – | – |
Press releases
Announcements Intellia Therapeutics filed with the SEC
Intellia Therapeutics Announces FDA Acceptance of Biologics License Application with Priority Review for Lonvoguran Ziclumeran (Lonvo-z) for Hereditary Angioedema (HAE)
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Debt Facility with OrbiMed for up to $400 Million
Material agreement · New financial obligation · Regulation FD disclosure · EX-99.1 to Form 8-K
Intellia Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates
Results of operations · EX-99.1 to Form 8-K
Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Intellia Therapeutics Announces First Quarter 2026 Financial Results and Business Updates
Results of operations · EX-99.1 to Form 8-K
Intellia Therapeutics Reports Positive Phase 3 Results in Hereditary
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Phase 3 HAELO Clinical Trial: Topline Data for Lonvo-z April 27, 2026
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
AMENDMENT NO. 2 TO THE OPEN MARKET SALE AGREEMENT SM
Material agreement · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Intellia Therapeutics Announces FDA Lift of Clinical Hold on
Material agreement · Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Intellia Therapeutics Announces Fourth Quarter and Full-Year 2025
Results of operations · EX-99.1 to Form 8-K
Intellia Therapeutics Announces FDA Lift of Clinical Hold on
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Overview January 2026 Exhibit 99.1
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Intellia Therapeutics Presents Positive Pooled Phase 1/2 Data of Lonvoguran
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Intellia Therapeutics Presents Positive Longer-Term Phase 1 Data of Nexiguran
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Intellia Therapeutics Announces Third Quarter 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
Intellia Therapeutics Provides Update on MAGNITUDE Clinical Trials of
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Intellia Therapeutics Announces Positive Longer-Term Phase 1 Data for
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Intellia Therapeutics Announces Second Quarter 2025 Financial Results and Highlights Recent Company Progress
Results of operations · Executive or director change · EX-99.1 to Form 8-K
Intellia Therapeutics Announces Positive Three-Year Data from Phase 1 Trial of Lonvoguran Ziclumeran
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Intellia Announces Positive Two-Year Follow-Up Data from Ongoing Phase 1 Study of Nexiguran Ziclumeran (nex-z), in Patients with Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy at Peripheral Nerve Society Annual Meeting
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Intellia Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Company Progress
Results of operations · EX-99.1 to Form 8-K
Intellia Therapeutics Announces Fourth Quarter and Full-Year 2024 Financial Results and Highlights Recent Company Progress
Results of operations · EX-99.1 to Form 8-K
Intellia Therapeutics Announces Anticipated 2025 Milestones and
Results of operations · Exit or restructuring costs · Executive or director change · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Intellia Announces First Clinical Evidence from Ongoing Phase 1 Study that nexiguran ziclumeran (nex-z),
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Intellia Therapeutics Announces Third Quarter 2024 Financial Results and Highlights Recent Company Progress
Results of operations · EX-99.1 to Form 8-K
Intellia Presents Positive Results from the Phase 2 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Intellia Therapeutics Announces Second Quarter 2024 Financial Results and Highlights Recent Company Progress
Results of operations · EX-99.1 to Form 8-K
Intellia Therapeutics Announces CFO Transition
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Intellia Therapeutics Names Brian Goff to its Board of Directors
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Intellia Therapeutics Announces First Quarter 2024 Financial Results and Highlights Recent Company Progress
Results of operations · EX-99.1 to Form 8-K
Intellia Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Company Progress
Results of operations · EX-99.1 to Form 8-K
Intellia Therapeutics Announces Publication of Positive Interim Phase 1 Data for NTLA-2002 in Patients with Hereditary Angioedema in the New England Journal of Medicine
Regulation FD disclosure · EX-99.1 to Form 8-K
Intellia Therapeutics Highlights its Three-Year Strategic Priorities and
Results of operations · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Intellia Therapeutics Announces Third Quarter 2023 Financial Results and Highlights Recent Company Progress
Results of operations · EX-99.1 to Form 8-K
Intellia Presents New Interim Data
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
MADRID serum [TTR] as a biomarker for treatment of ATTR amyloidosis Julian D. Gillmore National Amyloidosis Centre, Division of Medicine, University College London on behalf of: 2 3 4 5 5 Jörg Täubel, Ed Gane, Björn Pilebro, Michael
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Intellia Therapeutics Announces FDA Clearance of
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Regeneron and Intellia Announce Expanded Research Collaboration
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Intellia Therapeutics Announces Second Quarter 2023 Financial Results and Highlights Recent Company Progress
Results of operations · EX-99.1 to Form 8-K
Intellia Therapeutics Announces New Positive Clinical Data from Phase 1 Study of
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K